Indivior PLC

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:01 2025-07-14 EDT			5-day change	1st Jan Change
1,167.00 ^GBX	+2.19%		+1.92%	+13.96%

07-08	Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025	CI
06-30	Indivior PLC(NasdaqGS:INDV) added to Russell 3000 Value Index	CI

Indivior PLC Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 2025-04-24 at 02:00

Indivior PLC reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 266 million compared to USD 284 million a year ago. Net income was USD 47 million compared to USD 61 million a year ago.

Basic earnings per share from continuing operations was USD 0.38 compared to USD 0.45 a year ago. Diluted earnings per share from continuing operations was USD 0.38 compared to USD 0.45 a year ago.

Latest news about Indivior PLC

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025	07-08	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000 Value Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000 Growth Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2000 Dynamic Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2500 Value Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000E Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell Small Cap Comp Growth Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000 Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2500 Growth Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell Small Cap Comp Value Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell Small Cap Completeness Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2000 Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000E Growth Index	06-30	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2000 Value Index	06-30	CI
Indivior to Join US Russell Indexes	06-30	MT
Indivior PLC(NasdaqGS:INDV) added to Russell 2000 Growth Index	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000E Value Index	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2500 Index	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2000 Value Benchmark	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2500 Value Benchmark	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000 Growth Benchmark	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 2500 Growth Benchmark	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000 Value Benchmark	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell Small Cap Comp Growth Benchmark	06-29	CI
Indivior PLC(NasdaqGS:INDV) added to Russell 3000E Growth Benchmark	06-29	CI

Chart Indivior PLC

Duration

Period

INDV: Dynamic Chart

Company Profile

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,041

Sector

Pharmaceuticals

Calendar

07-23 - Q2 2025 Earnings Release (Projected)

More about the company